Increasing access to transplantation through telemedicine and patient navigation
- PMID: 38775773
- DOI: 10.1016/j.jcyt.2024.05.006
Increasing access to transplantation through telemedicine and patient navigation
Abstract
Background: Hematopoietic cell transplantation (HCT) is a promising treatment for hematological diseases, yet access barriers like cost and limited transplant centers persist. Telemedicine-based patient navigation (PN) has emerged as a solution. This study presents a cost-free PN telemedicine clinic (TC) in collaboration with the National Marrow Donor Program.
Aim: to assess its feasibility and impac on HCT access determined by the cumulative incidence of transplantation.
Methods: In this single-center cohort study, patients of all ages and diagnoses referred for HCT participated. Two transplant physician-navigators established patient relationships via video calls, collecting medical history, offering HCT education and recommending pretransplant tests. The analysis involved descriptive statistics and intent-to-transplant survival assessment.
Results: One hundred and three patients were included of whom n = 78 were referred for allogeneic HCT (alloHCT), with a median age of 28 years. The median time from initial contact to the first consult was 5 days. The cumulative incidence of transplantation was 50% at 6 months and 61% at 12 months, with varying outcomes based on HCT type. Notably, 49 patients were not transplanted, primarily due to refractory disease, progression or relapse (57.1%). Autologous HCT candidates and physician referrals were correlated with higher transplant success compared to alloHCT candidates and patients who were not referred by a physician.
Conclusion: Our pretransplant TC was feasible, facilitating access to HCT. Disease relapse posed a significant barrier. Enhancing timely physician referrals should be a focus for future efforts.
Keywords: Hematopoietic stem cell transplantation; patient navigation; telemedicine; transplantation.
Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest Andrés Gómez-De León has declaration of competing interest with Amgen: honoraria, Astellas: honoraria. BMS: honoraria, Janssen: honoraria and advisory board. Novartis: honoraria, Pfizer: advisory board. Sanofi: honoraria. David Gómez-Almaguer has declaration of competing interest with Janssen: honoraria, advisory board; Roche: honoraria, advisory board; BMS: honoraria, advisory board; Takeda: honoraria, advisory board. And other authors do not have any declaration of competing interest disclose.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
